Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include BDX, MCK, COO and STAA.
BDX launches the Neopak XtraFlow Glass Prefillable Syringe, enhancing drug delivery for biologics and expanding capacity with new high-volume production lines.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BDX expands its smart care portfolio by acquiring Edwards Lifesciences' Critical Care group, now BD Advanced Patient Monitoring, strengthening AI-driven health solutions.
Becton, Dickinson and Company (NYSE:BDX ) Wells Fargo 2024 Healthcare Conference September 4, 2024 8:45 AM ET Company Participants Tom Polen - Chairman, President & CEO Conference Call Participants Lawrence Biegelsen - Wells Fargo Lawrence Biegelsen Welcome back. Good morning.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Dividends have played a significant role in the total returns of equity investments. The practice of consistently increasing dividends can be seen in the S&P 500 Dividend Aristocrats.
Becton, Dickinson is overwhelmingly considered undervalued by Wall Street analysts, with an average price target of ~$280 and highs of $312-$330. This is supported by my extensive DCF and comps models. BDX benefits from innovative products, strategic partnerships, and ongoing trends. The company boasts high margins and a reliable, growing dividend. However, the price is already pretty close to its all-time high and most price targets, so significant further appreciation is unlikely, making BDX a very moderate "Buy".
BD's (BDX) overall topline benefits from revenue growth in all segments in the fiscal third quarter.